Previous Article | Next Article 
Journal of Virology, March 2000, p. 2541-2549, Vol. 74, No. 6
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Evolutionary Rate and Genetic Drift of Hepatitis C
Virus Are Not Correlated with the Host Immune Response: Studies of
Infected Donor-Recipient Clusters
Jean-Pierre
Allain,1,*
Yan
Dong,1,2
Anne-Mieke
Vandamme,3
Vincent
Moulton,4 and
Marco
Salemi3
Division of Transfusion Medicine, Department
of Haematology,1 and National Blood
Service,2 East Anglia Blood Centre, Cambridge,
United Kingdom; Riga Institute for Medical Research, KU,
Leuven, Belgium3; and FMI, Physics
and Mathematics Department, Mid Sweden University, Sundsvall,
Sweden4
Received 2 September 1999/Accepted 13 December 1999
 |
ABSTRACT |
Six donor-recipient clusters of hepatitis C virus (HCV)-infected
individuals were studied. For five clusters the period of infection of
the donor could be estimated, and for all six clusters the time of
infection of the recipients from the donor via blood transfusion was
also precisely known. Detailed phylogenetic analyses were carried out
to investigate the genomic evolution of the viral quasispecies within
infected individuals in each cluster. The molecular clock analysis
showed that HCV quasispecies within a patient are evolving at the same
rate and that donors that have been infected for longer time tend to
have a lower evolutionary rate. Phylogenetic analysis based on the
split decomposition method revealed different evolutionary patterns in
different donor-recipient clusters. Reactivity of antibody against the
first hypervariable region (HVR1) of HCV in donor and recipient sera
was evaluated and correlated to the calculated evolutionary rate.
Results indicate that anti-HVR1 reactivity was related more to the
overall level of humoral immune response of the host than to the HVR1
sequence itself, suggesting that the particular sequence of the HVR1
peptides is not the determinant of reactivity. Moreover, no correlation was found between the evolutionary rate or the heterogeneity of the
viral quasispecies in the patients and the strength of the immune
response to HVR1 epitopes. Rather, the results seem to imply that
genetic drift is less dependent on immune pressure than on the rate of
evolution and that the genetic drift of HCV is independent of the host
immune pressure.
 |
INTRODUCTION |
Hepatitis C virus (HCV) causes
persistent infection in a majority of infected individuals. Among the
possible mechanisms explaining persistence are the relatively poor
immunogenicity of the virus, particularly of the envelope
glycoproteins; the low level of viremia outside the preseroconversion
period; and the considerable variability of the viral genome, leading
to substantial changes in the viral epitopes over time in the same
individual (22, 36). One of the main contributors to these
genomic changes is the hypervariable region 1 (HVR1) located at the N
terminus of the major envelope glycoprotein E2. Mutations in HVR1,
which is critical for virus interaction with target cells (34,
48), produce escape mutants, a likely contributing factor to
viral persistence (24, 38, 46).
The host of HCV, primate or human, seems in most cases unable to
generate an effective immune response, whether humoral, as levels of
antibody to the E2 protein or HVR1 are typically low or undetectable,
or cellular, as no evidence of a specific T-cell response to E2
epitopes has been provided (3, 16, 17, 37). This feature was
supported by data collected in vivo indicating that neither natural
defenses nor passive immunotherapy was able to prevent reinfection of a
chronically infected patient or animal with the same or related viruses
(7, 30).
Some studies of HCV evolution over time, in the same infected
individual or in different individuals infected with the same viral
quasispecies, have been reported (1, 43, 46). Conflicting findings of the relative contribution of the virus itself or of the
selecting pressure exercised by the host immune system were provided
(18, 19, 47, 49). To further examine this question, we
studied the viral population as well as the humoral immune response to
HVR1 of clusters of HCV-infected blood donors and recipients of blood
components from these donors. Evolutionary rates and phylogeny of
donor-recipient pairs were determined and compared to the magnitude and
the specificity of the anti-HVR1 response.
 |
MATERIALS AND METHODS |
Donors and patients.
Six donor-recipient clusters totaling
21 HCV-infected individuals were included in the study. Clusters were
selected on the basis of blood components from each donor being the
origin of HCV infection of at least two recipients. All six donors were identified as anti-HCV and HCV RNA positive between October 1991 and
May 1992. They ranged in age between 34 and 45 years at the time of HCV
infection diagnosis; three were males and three were females. Two had
moderate elevation of alanine aminotransferase (ALT) (donors of
clusters 2 and 5 [c2.d and c5.d]) with stage 3 and 0 fibrosis,
respectively. The other four donors neither were tested for ALT nor had
liver biopsy. Donor c1d had a level of viremia estimated to
104 genome equivalents/ml. Fifteen recipients of previous
donations from these donors were identified and tested for antibody to
HCV at the end of 1995 within the scope of the National Blood Service look-back program. There were seven males and eight females, ranging in
age between 13 and 83 (median, 64) years. Of the 10 recipients tested
for ALT, only two recipients 2 of clusters 1 and 5 [c1.r2 and c5.r2]
had elevated levels (91 and 134 IU, respectively). Seven of nine
patients had no clinical evidence of liver disease. Recipients c1.r3
and c1.r4 had liver histology staged at 0 and 1 for fibrosis.
Estimation of HCV viremia was not part of the study protocol. The date
of infection was precisely known for only two donors of clusters 4 and
6 who received a presumably infected transfusion in 1983 and 1971, respectively, and had no other risk factors. Donors of clusters 2, 3, and 5 were former intravenous drug abusers. Donors of clusters 2, 3, and 5 were active in 1970, 1972 to 1974, and 1975, respectively. The
donor of cluster 1 did not have any identifiable risk factor, and his date of infection remained unknown.
All 15 recipients were diagnosed as HCV infected on the basis of
seropositivity, confirmation by recombinant immunoblot assay version 3 (RIBA-3) in 13 and the presence of HCV RNA in 2. The presumably
infectious transfusions were received 11.2 to 4.4 (years.months) prior
to diagnosis (median, 7.5) when the studied sample was obtained. Recipients (nine males and six females) ranged in age between 13 and 82 (median, 59) years. Ten of these 15 recipients were found to be HCV RNA
positive, and the HCV genome was amplified and sequenced. The other
five recipients were HCV seropositive but RNA negative or, in one of
them, the E1/E2 region could not be amplified. Serum samples of these
five patients were used for serological analysis of HVR peptide reactivity.
HCV RNA studies.
HCV viremia was determined by reverse
transcription-PCR, using nested primers in the 5' noncoding region, as
previously described (31). To determine the quasispecies
diversity, the E1/E2 region was amplified and sequenced as described
elsewhere (20). Nine to 15 cDNA clones were sequenced in
order to identify mutations and to estimate the diversity of variants
in each specimen's quasispecies. For each sample, a 258-nucleotide
(nt)-long sequence encompassing the 3' end of E1 and HVR1 (nt 1362 to
1620) (5) was obtained. The HCV genotype was determined by
phylogenetic analysis using the whole sequence and reference sequences
from HCV genotypes 1 to 5.
Phylogenetic analysis.
Forty-six DNA sequences from donors
and recipients belonging to the different clusters were aligned with 10 HCV sequences from the EMBL database, representing HCV subtypes 1 to 5, with the Clustal software (11). The HCV sequences used as
reference (with accession numbers indicated in brackets) were HCV1a
[M62321], hcg2.1b [D10074], and HC.G9.1c [D14853] for subtype 1;
hcj6.2a [D00944], hcj8.2b [D10988], and hcj5.2c [D10076] for subtype 2; hem265.3a [D14311] and HCV.3b [D26556] for subtype 3;
ED43 [Y11604] for subtype 4a; and EUH1480.5a for subtype 5. The last
sequence was kindly provided by P. Simmonds, Edinburgh, United Kingdom.
In total, 56 HCV strains were aligned using a 258-nt sequence
corresponding to the E1/E2 region as described above.
Phylogeny construction and evaluation were done using PHYLIP 3.572 (
10). We used two different methods, neighbor joining
(NJ)
and maximum likelihood (ML), employing an empirical
transition/transversion
bias of 1.61 for both. The bias was estimated
with the ML method
implemented in PUZZLE (
42), using the HKY
model (
11). The
NJ tree was evaluated using 1,000 bootstrap
samples (
9);
P values for the branches of the ML
tree were also
obtained.
Molecular clock analysis and evolutionary rate.
To
investigate the dynamic of the viral quasispecies within each infected
individual of the six donor-recipient clusters, separate alignments
were obtained, each joining only the clones sequenced from the same
patient. The HKY model was chosen to estimate nucleotide distance
matrices and empirical transition transversion ratios for the different
data sets with the program PUZZLE (42), as described above.
To determine whether the viral quasispecies evolved at constant rate
within a patient, we tested the molecular clock hypothesis for every
data set with the likelihood ratio test (LRT), also implemented in
PUZZLE. To perform the test, a phylogenetic tree is obtained, and then
the branch lengths and likelihood of the tree are calculated with or
without the assumption of constant evolutionary rate along the
branches. If the likelihood of the tree assuming the clock (simpler
model) is not significantly lower than the likelihood of the nonclock
tree (more complex model) in a
2 test with
n
2 degrees of freedom, where n is
the number of taxa, the molecular clock cannot be rejected
(14).
Since all of the data sets showed a clock-like behavior (see Results),
it was possible to calculate the evolutionary rate
of HCV in most
patients. In fact, for all infected individuals
except c1.d, the time
of infection was known with acceptable precision.
Under the clock
hypothesis, taxa sharing the same ancestor have
the same branch length
to their common ancestor. Thus for a particular
data set, the
evolutionary rate can be estimated by dividing one
of the branch
lengths connecting an HCV strain to the node representing
the ancestor
in common with all the other strains in the tree
by the difference
between time of infection and time of sampling
expressed in
years.
Test for positive or purifying selection.
The number of
nonsynonymous and synonymous substitutions, indicated by
KA and KS, respectively,
was computed for each donor-recipient cluster. A
KA/KS ratio significantly lower than
1 is evidence for the presence of purifying selection, whereas ratios
greater than 1 indicate positive selection. Within a particular
cluster, KA and KS values
were estimated comparing the sequences of the different clones with
another with the method of Nei and Gojobori (27) implemented
in the program MEGA, and their averages were used to compute average
KA/KS ratios.
Split decomposition analysis with Splitstree.
Evolutionary
relationships between taxa are most often represented as phylogenetic
trees, the justification being that evolution is usually a branching
tree-like process. However, in certain cases, the tree-like behavior of
the data in question cannot be guaranteed, in which case it can contain
a number of conflicting phylogenetic signals. Thus in these situations
it is appropriate to not necessarily force the data onto a tree but to
allow representation of the evolutionary relationship by networks that
can simultaneously display contradictory signals. To generate such
networks, we used SplitsTree 2.3f (15), a program based on
the split decomposition theory for analyzing metrics. Essentially, this
theory allows one to canonically decompose any distance (such as the
one generated from the data set presented) into the sum of split
metrics plus a split prime residue. Once computed, a network represents
the split metric sum (as appearing in Fig. 2) that approximates the metric in question. As this is an approximation, a fit index that indicates how well the network represents the original distance is also
computed; a fit index of 100% indicates true representation, whereas
lower fits imply reduction in accuracy. In general, if the distance
supplied is tree-like, then SplitsTree will produce a tree; more
complex networks result as the distance deviates from this ideal
situation. Several options are available in SplitsTree. We will make
use of the refine option, one that in certain cases allows an
improvement of the resolution of the generated SplitsTrees.
Peptide enzyme immunoassay.
Synthetic 15-mer C-terminal HVR1
(amino acids 13 to 27) peptides were prepared according to the
sequences deduced from the dominant and the most divergent nucleotide
sequences of each donor and recipient quasispecies. Peptides were
modified by the addition of a cysteine residue at the NH2
terminus, cross-linked through this residue to activated microtiter
plates (Covalab, Lyon, France), and used as antigens for the detection
of anti-HVR1 in autologous sera and in sera from individuals in the
same cluster (intracluster) and cross-reactivity with sera from donor
and recipients from other clusters as described previously
(3). Eight sera from random blood donors were also tested in
each microtiter plate as negative controls to determine the assay
cutoff (CO). Peptides were incubated for 30 min at room temperature,
and plates were extensively washed. After addition of a blocking
reagent at room temperature for another 30 min, 100 µl of
1:100-diluted serum samples were added and incubated for 60 min at
37°C. After five washings with phosphate-buffered saline containing
0.05% Tween 20 (pH 7.1), 100 µl of 1:2,000-diluted alkaline
phosphatase-labeled goat anti-human rabbit immunoglobulin G (Sigma) was
added, and the mixture was incubated for 60 min at 37°C.
P-Nitrophenyl phosphate substrate was extemporaneously
dissolved in Tris buffer; 100 µl was added to the wells, which were
then incubated for 30 min at room temperature in the dark. The reaction
was blocked by addition of 50 µl of 4 M sulfuric acid, and the
absorbance was read at 405 nm. For each peptide tested, a CO value was
calculated as the mean absorbance of eight negative control sera plus
six times the standard deviation (SD). Data were expressed as the ratio between the sample absorbance and the CO value (S/CO).
 |
RESULTS |
Quasispecies and genotypes.
From the 9 to 15 clones sequenced
in each patient, 5 to 12 variants were found at the nucleotide level in
the E1/E2 region. The number of variants ranged between 3 and 10 when
the analysis was restricted to the HVR1 region. The HVR1 region
accounted for 61% of the diversity.
The phylogenetic analysis of the E1/E2 nucleotide sequences together
with appropriate homologous reference sequences permitted
genotyping.
In the NJ tree shown in Fig.
1, in
addition to reference
sequences specific of the HCV-specific genotypes
1 to 5, the most
representative variants of E1/E2 sequences from each
individual
in the study are indicated. The ML tree gave almost the same
topology.
As shown in Fig.
1, clusters 2, 4, 5, and 6 belong to
genotype
1. In particular, clusters 4 and 5 are monophyletic with the
HCV
reference strain of the 1a subgroup (97.9% bootstrap support;
P < 0.01 in the ML tree), while cluster 6 belongs to
the 1b subgroup
(100% bootstraps;
P < 0.01). Cluster
2 is clearly separated from
the other three clusters as well as from
the reference sequence
for genotypes 1a, 1b, and 1c with very high
bootstrap support
(Fig.
1). This might correspond to a separate
subgroup of genotype
1 or to a divergent strain within the 1a subgroup.
Clusters 1
and 3 are monophyletic with the reference sequences of
genotypes
3a and 2b, respectively, with very high bootstrap support
(Fig.
1). Recipient 2 of cluster 3 was found to harbor genotype 3a
(data
not shown), clearly different from both the donor and recipient
1 of the same cluster (2b). The history of this patient revealed
that he
had been transfused with an HCV-seropositive blood component
1 year
prior to the index transfusion. Although no sample from
the
corresponding donor was available, it appeared very likely
that the
first infection was with an HCV strain of genotype 3a
and that the
index transfusion either was not infectious or did
not yield
superinfection with genotype 2b. This recipient was
excluded from
further studies.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Genotyping of six donor-recipient clusters. Unrooted NJ
phylogenetic tree of the HCV 258-nt consensus E1/E2 region, including
HVR1. Reference sequences of known genotypes are in boldface. Donors
and recipients from the six clusters studied are indicated as follows:
cluster number (c1 to c6), d for donor, r1 and r2 for recipients 1 and
2, and number of the most representative variants for each
quasispecies. Bootstrap percentages of 1,000 bootstrap replicates are
given along the appropriate branches. Bootstrap values <50% are not
shown. All clades for which the bootstrap values are indicated were
also supported by P values of <0.01 in the ML tree, except
for the P < 0.05 indicated in the figure.
|
|
HCV evolutionary rates in different patients.
Several cDNA
clones were sequenced and aligned for each patient to investigate the
diversity of the viral quasispecies within any infected individual.
Genetic distances among the different strains of a patient were
computed with the HKY model (11), which provided the
best-fitting model for these particular data sets (data not shown).
Heterogeneity of nucleotide substitution rates across sites was tested
assuming a discrete
distribution of the rates (with eight rate
categories) and estimating the
parameter of the distribution with
the program PUZZLE (42). Most of the data sets gave
values greater than 50, suggesting uniform rates across sites (data not
shown). Exceptions were recipient 1 in cluster 2 and the recipient in
cluster 6, with
values of 0.1 and 0.28, respectively. Thus, for
these two data sets, distances were estimated employing the HKY model
with rate heterogeneity. Finally, the LRT for the molecular clock
hypothesis was performed as described in Materials and Methods. The
results of the LRT for each data set are given in Table
1. Within any infected individual, the
virus accumulates mutations over time at a constant rate.
The estimated HCV evolutionary rate in each patient is given in Table
2. The rates range from 3.4 × 10
4 to 4.51 × 10
3 nucleotide
substitutions per site per year. However, the
t test
shows
that only in the donors of clusters 2, 5, and 6 was the
evolutionary
rate significantly lower than in the corresponding
recipients (Table
2). Moreover, pairs of recipients infected
by the same donor did not
show a statistically significant difference
in evolutionary rate.
Analysis of selective pressure.
Table
3 indicates the average of nonsynonymous
and synonymous nucleotide substitutions among the different clones
sequenced in each donor-recipient cluster.
KA/KS appears to be greater than 1 for clusters 1, 4, and 6 and less than 1 for clusters 2, 3, and 5. However, none of the clusters show a statistically significant difference between KA and
KS values (Table 3).
SplitsTree analysis.
Refined SplitsTrees obtained for each
cluster are shown in Fig. 2. Unrefined
SplitsTrees were almost identical. The fit indices for clusters 1, 3, 4, and 5 were good, ranging between 79 and 96%; cluster 2 had the
lowest fit (68%). The pattern of donor versus recipient(s) is clear in
each of these SplitsTrees except in cluster 2, where a more complex
network is obtained. The donor and each of the two recipients in
cluster 1, the donor and recipient in clusters 3 and 4, and the donors
of clusters 5 and 6 show one or two strains at an internal node giving
rise to the other strains in their respective SplitsTrees. For each of
these cases, Splitstree was run separately on both the donor and
recipient subclusters. In all cases except the donor subcluster of
cluster 6, a tree was obtained with 100% fit.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 2.
SplitsTrees obtained with the split decomposition method
for the six donor-recipient clusters studied, designated as for Fig. 1.
Squares indicate the different clones sequenced in each patient.
|
|
Even though the remaining cases (donor and two recipients of cluster 2, the two recipients in cluster 5, and the recipient
in cluster 6)
exhibit a more complicated pattern of splits with
several distinct
viral lineages, it was found that the SplitsTrees
for the donor and
recipient subclusters were in most cases extremely
tree-like; the
exception was cluster 2, where one of the recipient's
SplitsTrees had
a net structure with 100% fit. Finally, the SplitsTrees
seem to
indicate differing phylogenetic relationships between
the donor and
recipient for each of the six clusters. In particular,
in clusters 1, 2, 3, and 4, the donor subnetwork is connected
to that of the
recipient(s) by at least three edges, whereas in
clusters 5 and 6, only
two and one edges, respectively, are found.
However, in most cases
where several edges joined the donor and
recipient, such as in clusters
1, 3, and 4, the removal of a single
taxon from the data set and
subsequent recomputation of the SplitsTree
resulted in the
disappearance of the box (data not shown). This
suggests that these
splits are supported by only one
taxon.
Immunological reactivity with HVR1 peptides.
To examine the
influence of immune pressure on the evolutionary patterns of HCV in the
donor-recipient pairs, reactivities of HVR1 antibody in donor and
recipient sera were tested with autologous and heterologous HVR1
peptides. Peptide sequences were derived from the dominant variant of
each patient quasispecies, and when appropriate, additional peptides
were derived from substantially divergent variants. As shown in Table
4, only sera from the donor of cluster 2 and recipient 1 of cluster 3 strongly reacted with the autologous
peptides. Sera from six individuals did not recognize autologous
peptides. In particular, no member of cluster 1 reacted with autologous
peptides, and only serum from recipient 1 had low reactivity with both
peptides from other cluster members. The average S/CO ± 1 SD of
reactive patient sera was not significantly different between
autologous, intracluster, or extracluster peptides (2.85 ± 2.77, 1.83 ± 0.80, and 2.05 ± 1.75, respectively). However, when
levels of reactivity with the panel of HVR1 peptides were compared
between sera, they tended to be the highest with extracluster and then
intracluster peptides and lowest with autologous peptides. This
analysis was in part confounded by the fact that sera from five
individuals (donors from cluster 2 and 5; recipients 1 from clusters 3, 4, and 5) reacted with 14 to 18 of the 20 peptides tested. These sera
were considered highly reactive against HVR1 epitopes. Sera from other
patients reacted with eight or fewer peptides. As shown in Fig.
3, there was a correlation between the
number of peptides recognized by each serum and the S/CO taken as a
reflection of the level of antibody. This observation suggests that
infected patients who develop antibody to HVR1 with high levels of
reactivity to HVR1 peptides, autologous or heterologous, also have the
broadest cross-reactivity.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 3.
Correlation between the number of reactive HVR1 peptides
from donors and recipients and level of reactivity by enzyme
immunoassay expressed as S/CO. CO was defined as the mean of the
optical density of eight negative control sera plus 6 SD. The equation
of the regression line and the R2 value are
indicated.
|
|
High level and frequency of reactivity were associated with peptides
from donors of cluster 1 and 2 (17 and 18 of 21 sera
were reactive).
Five other peptides (c2.r1a, c3.d, c3.r1, c6.d,
and c6.r1b) reacted
with 13 of the 21 sera. These results indicate
that anti-HVR1
reactivity was more related to the overall level
of humoral immune
response of the host than the HVR1 sequence,
whether HVR1 peptides
derived from autologous, intracluster, or
extracluster sequences. There
was no correlation between the level
of reactivity and the breadth of
antigen recognition of sera from
HCV-infected patients tested with HVR1
peptides derived from individuals
infected with unrelated HCV
strains. This suggests that the particular
sequence of the HVR1
peptides is not the determinant of antibody
reactivity.
The potential correlation between evolutionary rate and anti-HVR1
immune reactivity was assessed by plotting the data presented
in Table
2 with two indicators of immune response to HVR1 epitopes
(Fig.
4). The first indicator was the serum
reactivity with autologous
HVR1 peptides expressed as S/CO; the second
was the ratio between
the number of extracluster HVR1 peptides
recognized by each serum
(S/CO

1) and the total number of
peptides tested (range, 15
to 18) (Table
3). No correlation was found
between the evolutionary
rate and either of these immunological
indicators.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 4.
Evolutionary rate and HVR1 immune response. Absence of
correlation between evolutionary rate and anti-HVR1 reactivity. Open
squares correspond to the reactivity of patient plasma against
autologous HVR1 peptides. When two different peptides derived from a
patient's quasispecies, two data points are indicated. Diamonds
correspond to the number of reactive peptides of each plasma against
all extracluster HVR1 peptides divided by the number of peptides
tested.
|
|
 |
DISCUSSION |
HCV is an RNA virus chronically infecting humans and chimpanzees.
The viral genome is submitted to a very large number of replication
cycles over decades, and since transcription is not proofread, errors
occur which result in the presence of a family of related genomic
variants called quasispecies (23). Relatively little is
known about the rate of genetic errors driving over time the drift of a
given population of HCV variants (4, 28, 40, 41). The host
is the second factor potentially involved in changes of the
quasispecies. The immune system of the infected host develops both
humoral and cellular immune responses which contribute to limiting the
level of viral replication (29). Genomic viral diversity
translates into different amino acid sequences and epitopes, resulting
in different levels of recognition by the host immune system
(7). Some epitopes are not recognized, and the corresponding
variants, named escape mutants, circulate in a free form and probably
benefit from a replication advantage (2, 18, 47). The others
variants, more numerous, circulate as immune complexes with antibodies
bound to the external glycoproteins (2, 8, 39). It has been
recognized that the E1/E2 region, in particular the hypervariable
N-terminal region of E2, played a major role in the escape mechanism
(38, 45). However, the relative parts played by the virus's
inherent ability to mutate and the ability of the host immune system to
apply pressure and participate in the viral diversity by selecting
particular variants have not been clearly established (3, 20, 22,
30, 43). In the work presented here, inclusion of multiple
recipients of HCV from an infected blood donor ensured that two
different individuals were, at a known time, chronically infected or
contaminated with the same quasispecies. By studying the phylogeny of
these donor-recipient pairs and the anti-HVR1 patient-specific immune
response, it became possible to determine the relative contributions of
the virus and the host in viral evolution.
We first established that donor-recipient pairs in each cluster were
related to each other and were of the same genotype. This is clearly
demonstrated in the phylogenetic tree shown in Fig. 1. The excess of
clusters of genotype 1 is in accordance with the prevalence of HCV
genotypes in the United Kingdom (21, 25, 44). The only
exception was recipient 2 of cluster 3, whose genotype differed from
the implicated donor and the other recipient in the cluster. A likely
explanation for this anomaly was found in this individual's
transfusion history. From previous data collected by our group and by
others, it seemed that the 9 to 15 clones sequenced in each patient
were adequate to provide a reliable appreciation of the quasispecies
diversity (3, 20). The main feature of the data presented
here is that the HCV evolutionary rate in all patients is compatible
with an intrapatient molecular clock hypothesis (Table 1). The virus
seems to accumulate mutations at the same rate for all variants within
a particular infected individual. Since the time of the infection was
known for most of the patients, it was also possible to estimate the
HCV evolutionary rate in the different hosts. When these evolutionary
rates were correlated with the patient level of immune response
(estimated according to the number of HVR1 peptides recognized and the
level of reactivity [Table 3 and Fig. 3]), no relationship was
observed. It therefore appears that HCV genomic drift is mostly
independent of the host level or breadth of humoral immune response to
HVR1 and could be essentially driven by viral replication errors and the number of replication cycles. This conclusion is also supported by
the observation that analyses of nonsynonymous and synonymous replacements within the E1/E2 region do not show the presence of strong
positive or negative selection. A trend toward higher HVR1
KA/KS ratios in patients with
persistent viremia has recently been reported (33). We
indeed find a higher KA/KS ratio in
some cases, but the difference between KA and
KS is not statistically significant in any of
the clusters studied, suggesting neutral evolution. This conclusion has
to be viewed with caution, given the limited number of patients and the
fact that we could analyze only one time point after the occurrence of
HCV infection. However, the fact that results of all of the different
analyses performed appear to be in agreement strengthens our confidence
in the result. Viral diversity and evolutionary rates have been
evaluated in agammaglobulinemic patients and found to be very low
(19, 29). This finding could be taken as evidence that
without immune pressure, HCV genetic drift is reduced to the viral
internal clock. However, the sequences studied were taken from
consensus without examining quasispecies distribution and studied at a
very late stage, when patients had developed cirrhosis. In addition,
the evolutionary rates found in immunocompetent controls ranged between
0.1 and 0.28 nucleotide substitutions per site per year
(29), while based on the sequencing of at least 10 clones,
we observed a range of 0.34 to 4.51. The data sets do not appear comparable.
The viral quasispecies were studied between 4.4 and 23 years after
infection (Table 2), a relatively long period of time that does not
exclude that the host immune pressure could be more visibly effective
in the early part of this long-term, chronic infection. This concept is
indirectly supported by the observation that antibodies to the
N-terminus epitopes of HVR1 are found early in the infection,
particularly when self-limiting, but not after chronic infection is
established (3, 48).
It was, however, noticeable that the evolutionary rate of recipients
tended to be higher than that of donors who had been infected for a
considerably longer period of time (Table 2). This may reflect the
relative increase of evolutionary rate during the initial phase of the
infection when HCV replicates at a very high rate (doubling time of
viral replication estimated at 1 day [M. Bush et al., personal
communication]) in the preseroconversion period. Later during the
course of the persistent infection, replication cycles are assumed to
be slower and to involve fewer infected cells owing to the relative
control exercised by the host (18, 30). Not surprisingly, a
gross relationship was observed between evolutionary rate and viral
diversity within the quasispecies. As shown in Fig. 2, both recipients
in clusters 2 and 5 and recipient 1 in cluster 6, who had higher
evolutionary rates (Table 1), had quasispecies composed of more
divergent variants and a more network-like phylogeny of the
quasispecies. Conversely, individuals with lower evolutionary rates
such as donors and recipients in clusters 3 and 4 (Fig. 2) had
quasispecies of limited diversity.
In this analysis, the fact that in donors who have been infected years
or decades previously, several variants or lineages of variants may
simultaneously replicate at approximately the same rate should also be
taken into account. In contrast, in recipients, as previously shown,
only a limited number of variants, presumably those circulating as free
virus, preferentially infect the host and are initially submitted to
intense replication cycles (2, 18, 30). The SplitsTree
analysis for clusters 1, 3, and 4 showed a tree-like structure with
100% fit. Moreover, in each cluster, the splits in the recipient seem
to be supported by only a single taxon (see Results). In view of the
quasispecies distribution of HCV, it is possible that in the data sets
we analyzed, only one variant of the donor viral strains was by chance
alone the one transmitted to the recipient. The split decomposition
method has already been used with some success in the study of viruses, as it does not presuppose the tree-likeness of the data analyzed (6, 32). SplitsTree seems to be a powerful tool for
investigating the dynamic of HCV evolution within an infected host. It
could potentially be used to make inferences about the variants
transmitted during the infection of a new host and the time of
infection. For example, in light of our observation and interpretation
of this data set, it appears likely that the donor of cluster 1 was infected a relatively short time before infecting the first recipient.
In conclusion, it is suggested that the immune response of the host is
not one of the main evolutionary forces driving the diversity of the
HCV quasispecies in an infected host within the investigated E1/E2
region. The evolutionary rate and consequently the extent of the
genetic drift of the quasispecies corresponded to the time of
infection: the longer the time, the lower the HCV rate of evolution.
This fact might have important implications for HCV pathogenesis and
treatment and deserves further attention.
 |
ACKNOWLEDGMENTS |
We are grateful for the financial support from UK Department of
Health grant 121-6510 to Yan Dong. The collaboration between the
Division of Transfusion Medicine, Cambridge, and the Riga Institute,
Leuven, was the result of the fifth European workshop on virus
evolution and molecular epidemiology, 1 to 4 September 1998, Leuven,
Belgium, which was sponsored by European Community grant BMH4-98-4830.
We are indebted to P. E. Hewitt, North London Blood Centre, who
provided some of the samples, and to C. Llewelyn, East Anglia Blood
Centre, who provided information relative to the history of donors and recipients.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Transfusion Medicine, East Anglia Blood Centre, Long Road, Cambridge,
United Kingdom. Phone: 44 1223 548044. Fax: 44 1223 242044. E-mail:
jpa1000{at}cam.ac.uk.
 |
REFERENCES |
| 1.
|
Abe, K.,
G. Inchauspé, and K. Fujisawa.
1992.
Genomic characterisation and mutation rate of hepatitis C virus isolated from a patient who contracted hepatitis during an epidemic on non-A, non-B hepatitis in Japan.
J. Gen. Virol.
72:2725-2729.
|
| 2.
|
Aiyama, T.,
K. Yoshioka,
A. Okumura,
M. Takayanagi,
K. Iwata,
T. Ishikawa, and S. Kakuma.
1996.
Sequence analysis of hypervariable region of hepatitis C virus (HCV) associated with immune complex in patients with chronic HCV infection.
J. Infect. Dis.
174:1316-1320[Medline].
|
| 3.
|
Allain, J.-P.,
W. Zhai,
D. Shang,
E. Timmers, and G. J. M. Alexander.
1999.
Hypervariable region diversity of hepatitis C virus and humoral response: comparison between patients with and without cirrhosis.
J. Med. Virol.
59:25-31[CrossRef][Medline].
|
| 4.
|
Casino, C.,
J. McAllister,
F. Davidson,
J. Power,
E. Lawlord,
P. L. Yap,
P. Simmonds, and D. B. Smith.
1999.
Variation of hepatitis C virus following serial transmission: multiple mechanisms of diversification of the hypervariable region and evidence for convergent genome evolution.
J. Gen. Virol.
80:717-725[Abstract].
|
| 5.
|
Choo, Q. L.,
K. H. Richman,
J. H. Han,
K. Berger,
C. Lee,
C. Dong,
C. Gallegos,
D. Coit,
R. Medina-Selby, and P. J. Barr.
1991.
Genetic organisation and diversity of the hepatitis C virus.
Proc. Natl. Acad. Sci. USA
88:2451-2455[Abstract/Free Full Text].
|
| 6.
|
Dopazo, J.,
A. Dress, and A. von Haeseler.
1993.
Split decomposition: a technique to analyse viral evolution.
Proc. Natl. Acad. Sci. USA
90:10320-10324[Abstract/Free Full Text].
|
| 7.
|
Farci, P.,
H. J. Alter,
S. Govindarajan,
D. C. Wong,
R. Engle,
R. R. Lesniewski,
I. K. Mushahwar,
S. M. Desai,
R. H. Miller, and N. Ogata.
1992.
Lack of protective immunity against reinfection with hepatitis C infection.
Science
25:135-140.
|
| 8.
|
Farci, P.,
A. Shimoda,
D. Wong,
T. Cabezon,
D De Gionnis,
A. Strazzera,
Y. Shimizu,
M. Shapiro,
H. J. Alter, and R. H. Purcell.
1996.
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.
Proc. Natl. Acad. Sci. USA
93:15394-15399[Abstract/Free Full Text].
|
| 9.
|
Felsenstein, J.
1985.
Confidence limits on phylogenies: an approach using the bootstrap.
Evolution
39:783-791[CrossRef].
|
| 10.
|
Felsenstein, J. P.
1989.
Phylogeny inference package (version 3.2).
Cladistics
5:164-166.
|
| 11.
|
Hasegawa, M.,
H. Kishino, and T. Yano.
1985.
Dating the human-ape splitting by a molecular clock of mitochondrial DNA.
J. Mol. Evol.
22:160-174[CrossRef][Medline].
|
| 12.
|
Higgins, D. G.,
A. J. Bleasby, and R. Fuchs.
1992.
CLUSTAL V: improved software for multiple sequence alignment.
CABIOS
8:189-191[Abstract/Free Full Text].
|
| 13.
|
Higgins, D. G., and P. M. Sharp.
1988.
Clustal: a package for performing multiple sequence alignments on a microcomputer.
Gene
73:237-244[CrossRef][Medline].
|
| 14.
|
Huelsenbeck, J., and B. Rannala.
1997.
Phylogenetic methods come of age: testing hypotheses in an evolutionary context.
Science
276:227-232[Abstract/Free Full Text].
|
| 15.
|
Huson, D. H.
1997.
SplitsTree: a program for analyzing and visualizing evolutionary data.
University of Bielefeld, Bielefeld, Germany.
|
| 16.
|
Jackson, P.,
J. Petrik,
G. J. M. Alexander,
J. Pearson, and J.-P. Allain.
1997.
Reactivity of synthetic peptides representing selected sections of hepatitis C virus core and envelope proteins with a panel of hepatitis C virus-seropositive human plasma.
J. Med. Virol.
51:67-79[CrossRef][Medline].
|
| 17.
|
Kato, N.,
H. Sekiya,
Y. Ootsuyama,
T. Nakazawa,
M. Hijikata,
S. Ohkoshi, and K. Shimotohno.
1993.
Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus.
J. Virol.
67:3923-3930[Abstract/Free Full Text].
|
| 18.
|
Kojima, M.,
T. Osuga,
F. Tsuda,
T. Tanaka, and H. Okamoto.
1994.
Influence of antibodies to the hypervariable region of E2/NS1 glycoprotein on the selective replication of hepatitis C virus in chimpanzees.
Virology
200:665-672.
|
| 19.
|
Kumar, U.,
J. Monjardino, and H. C. Thomas.
1994.
Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient.
Gastroenterology
106:1072-1075[Medline].
|
| 20.
|
Lawal, Z.,
J. Petrik,
V. S. Wong,
G. J. M. Alexander, and J.-P. Allain.
1997.
Hepatitis C virus genomic variability in untreated and immunosuppressed patients.
Virology
228:107-111[CrossRef][Medline].
|
| 21.
|
Majid, A.,
R. Holmes,
U. Desselberger,
P. Simmonds, and T. A. McKee.
1995.
Molecular epidemiology of hepatitis C virus infection amongst intravenous drug users in rural communities.
J. Med. Virol.
46:48-51[Medline].
|
| 22.
|
Majid, A.,
P. Jackson,
Z. Lawal,
G. M. J. Pearson,
H. Parker,
G. J. M. Alexander,
J.-P. Allain, and J. Petrik.
1999.
Ontogeny of hepatitis C virus (HCV) hypervariable region 1 (HVR1) heterogeneity and HVR1 antibody responses over a three year period in a patient infected with HCV type 2b.
J. Gen. Virol.,
80:317-325[Abstract].
|
| 23.
|
Martell, A. R.,
J. I. Esteban,
J. Quer,
J. Genesca,
A. Weiner,
R. Esteban,
J. Guardia, and J. Gomez.
1992.
Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution.
J. Virol.
66:3225-3229[Abstract/Free Full Text].
|
| 24.
|
McAllister, J.,
C. Casino,
F. Davidson,
J. Power,
E. Lawlor,
P. L. Yap,
P. Simmonds, and D. B. Smith.
1998.
Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort.
J. Virol.
72:4893-4905[Abstract/Free Full Text].
|
| 25.
|
McOmish, F.,
S. W. Chan,
B. C. Dow,
J. Gillon,
W. D. Frame,
R. J. Crawford,
P. L. Yap,
E. A. C. Follett, and P. Simmonds.
1993.
Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities.
Transfusion
33:7-13[CrossRef][Medline].
|
| 26.
|
Mondelli, M. U.,
A. Cerino,
A. Lisa,
S. Brambilla,
L. Segagni,
A. Cividini,
M. Bissolati,
G. Missale,
G. Bellati,
A. Meola,
B. Bruniercole,
A. Nicosia,
G. Galfre, and E. Silini.
1997.
Antibody response to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation.
Hepatology
30:537-545[CrossRef].
|
| 27.
|
Nei, M., and T. Gojobori.
1986.
Simple method for estimating the numbers of synonymous and nonsynonymous nucleotide substitutions.
Mol. Biol. Evol.
3:418-426[Abstract].
|
| 28.
|
Ni, Y. H.,
M. H. Chang,
P. J. Chen,
H. H. Lin, and H. Y. Hsu.
1997.
Evolution of hepatitis C virus quasispecies in mothers and infants infected through mother-to-infant transmission.
J. Hepatol.
26:967-974[CrossRef][Medline].
|
| 29.
| Odeberg, J., Z. Yun, A. Sonneborg, K. Bjoro, M. Ulhen,
and J. Lundenberg. Variation of hepatitis C virus hypervariable
region 1 in immunocompromised patients. J. Infect. Dis.
175:938-943.
|
| 30.
|
Okamoto, H.,
S. Mishiro,
H. Tokita,
F. Tsuda,
Y. Miyakawa, and M. Mayumi.
1994.
Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a.
Hepatology
20:1131-1134[CrossRef][Medline].
|
| 31.
|
Petrik, J.,
G. J. M. Pearson, and J.-P. Allain.
1997.
High throughput PCR detection of HCV based on semiautomated multisample RNA capture.
J. Virol. Methods
64:147-159[CrossRef][Medline].
|
| 32.
|
Plikat, U.,
K. Nieselt-Struwe, and A. Meyerhans.
1997.
Genetic drift can dominate short-term human immunodeficiency virus type 1 nef quasispecies evolution in vivo.
J. Virol.
71:4233-4240[Abstract].
|
| 33.
|
Ray, C. S.,
Y.-M. Wang,
O. Laeyendecker,
J. R. Ticehurst,
S. A. Villano, and D. L. Thomas.
1999.
Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy.
J. Virol.
73:2398-2346.
|
| 34.
|
Rosa, D.,
S. Campagnoli,
C. Moretto,
E. Guenzi,
L. Cousens,
M. Chin,
C. Dong,
A. J. Weiner,
J. Y. N. Lau,
Q. L. Choo,
D. Chien,
P. Pileri,
M. Houghton, and S. Abrignani.
1996.
A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.
Proc. Natl. Acad. Sci. USA
93:1759-1763[Abstract/Free Full Text].
|
| 35.
|
Saitou, N., and M. Nei.
1987.
The neighbor-joining method: a new method for reconstructing phylogenetic trees.
Mol. Biol. Evol.
4:406-425[Abstract].
|
| 36.
|
Sakamoto, N.,
N. Enomoto,
M. Kurosaki,
F. Marumo, and C. Sato.
1993.
Sequential change of the hypervariable region of the hepatitis C virus genome in acute infection.
J. Med. Virol.
42:103-108.
|
| 37.
|
Scarcelli, E.,
A. Cerino,
G. Esposito,
E. Silini,
M. U. Mondelli, and C. Traboni.
1995.
Occurrence of antibodies reactive with more than one variant of the putative envelope glycoprotein (gp70) hypervariable region 1 in viremic hepatitis C virus-infected patients.
J. Virol.
60:4407-4412.
|
| 38.
|
Shimizu, Y. K.,
M. Hijikata,
A. Iwamoto,
H. J. Alter,
R. H. Purcell, and H. Yoshikura.
1994.
Neutralizing antibodies against hepatitis C virus and emergence of neutralization escape mutant viruses.
J. Virol.
68:1494-1500[Abstract/Free Full Text].
|
| 39.
|
Shimizu, Y. K.,
H. Igarashi,
T. Kiyohara,
T. Cabezon,
P. Farci,
R. H. Purcell, and H. Yoshikura.
1996.
A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell culture.
Virology
223:409-412[CrossRef][Medline].
|
| 40.
|
Simmonds, P., and D. B. Smith.
1997.
Investigation of the pattern of diversity of hepatitis C virus in relation to times of transmission.
J. Viral Hepat.
4:69-71.
|
| 41.
|
Smith, D. B., and P. Simmonds.
1997.
Characteristics of nucleotide substitution in the hepatitis C virus genome: constraints on sequence change in coding regions at both ends of the genome.
J. Mol. Evol.
45:238-246[CrossRef][Medline].
|
| 42.
|
Strimmer, K., and A. von Haeseler.
1997.
Likelihood mapping: a simple method to visualize phylogenetic content of a sequence alignment.
Proc. Natl. Acad. Sci. USA
94:6815-6819[Abstract/Free Full Text].
|
| 43.
|
van Doorn, L. J.,
I. Capriles,
G. Maertens,
R. DeLeys,
K. Murray,
T. Kos,
H. Schellekens, and W. Quint.
1995.
Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses.
J. Virol.
69:773-778[Abstract].
|
| 44.
|
Watson, J.-P.,
A. M. Brind,
C. E. Chapman,
C. L. Bates,
F. K. Gould,
S. J. Johnson,
A. D. Burt,
J. Ferguson,
P. Simmonds, and M. F. Bassendine.
1996.
Hepatitis C virus epidemiology and genotypes in the north of England.
Gut
38:269-276[Abstract/Free Full Text].
|
| 45.
|
Weiner, A. J.,
H. M. Geysen,
C. Christopherson,
J. E. Hall,
T. J. Mason,
G. Saracco,
F. Bonino,
K. Crawford,
C. D. Marion, and K. A. Crawford.
1992.
Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections.
Proc. Natl. Acad. Sci. USA
89:3468-3472[Abstract/Free Full Text].
|
| 46.
|
Weiner, A. J.,
M. M. Thaler,
K. Crawford,
K. Ching,
J. Kansopon,
D. Y. Chien,
J. E. Hall,
F. Hu, and M. Houghton.
1993.
A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants.
J. Virol.
67:4365-4368[Abstract/Free Full Text].
|
| 47.
|
Wyatt, C. A.,
L. Andrus,
B. Brotman,
F. Huang,
D. H. Lee, and A. M. Prince.
1998.
Immunity in chimpanzees chronically infected with hepatitis C virus: role of minor quasispecies in reinfection.
J. Virol.
72:1725-1730[Abstract/Free Full Text].
|
| 48.
|
Zibert, A.,
E. Schreier, and M. Roggendorf.
1995.
Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment.
Virology
208:653-661[CrossRef][Medline].
|
| 49.
|
Zibert, A.,
W. Kraas,
H. Meisel,
G. Jung, and M. Roggendorf.
1997.
Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus.
J. Virol.
71:4123-4127[Abstract].
|
Journal of Virology, March 2000, p. 2541-2549, Vol. 74, No. 6
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Zehender, G., De Maddalena, C., Bernini, F., Ebranati, E., Monti, G., Pioltelli, P., Galli, M.
(2005). Compartmentalization of Hepatitis C Virus Quasispecies in Blood Mononuclear Cells of Patients with Mixed Cryoglobulinemic Syndrome. J. Virol.
79: 9145-9156
[Abstract]
[Full Text]
-
Brown, R. J. P., Juttla, V. S., Tarr, A. W., Finnis, R., Irving, W. L., Hemsley, S., Flower, D. R., Borrow, P., Ball, J. K.
(2005). Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. J. Gen. Virol.
86: 1931-1942
[Abstract]
[Full Text]
-
Herring, B. L., Tsui, R., Peddada, L., Busch, M., Delwart, E. L.
(2005). Wide Range of Quasispecies Diversity during Primary Hepatitis C Virus Infection. J. Virol.
79: 4340-4346
[Abstract]
[Full Text]
-
Love, A., Molnegren, V., Mansson, A.-S., Smaradottir, A., Thorsteinsson, S. B., Widell, A.
(2004). Evolution of hepatitis C virus variants following blood transfusion from one infected donor to several recipients: a long-term follow-up. J. Gen. Virol.
85: 441-450
[Abstract]
[Full Text]
-
Cantaloube, J.-F., Biagini, P., Attoui, H., Gallian, P., de Micco, P., de Lamballerie, X.
(2003). Evolution of hepatitis C virus in blood donors and their respective recipients. J. Gen. Virol.
84: 441-446
[Abstract]
[Full Text]
-
Meyer, K., Basu, A., Przysiecki, C. T., Lagging, L. M., Di Bisceglie, A. M., Conley, A. J., Ray, R.
(2002). Complement-Mediated Enhancement of Antibody Function for Neutralization of Pseudotype Virus Containing Hepatitis C Virus E2 Chimeric Glycoprotein. J. Virol.
76: 2150-2158
[Abstract]
[Full Text]
-
Li, C., Candotti, D., Allain, J.-P.
(2001). Production and Characterization of Monoclonal Antibodies Specific for a Conserved Epitope within Hepatitis C Virus Hypervariable Region 1. J. Virol.
75: 12412-12420
[Abstract]
[Full Text]
-
Sironen, T., Vaheri, A., Plyusnin, A.
(2001). Molecular Evolution of Puumala Hantavirus. J. Virol.
75: 11803-11810
[Abstract]
[Full Text]